This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Angion Biomedica Beheer

Beheer criteriumcontroles 3/4

De CEO Angion Biomedica is Jay Venkatesan, benoemd in May2018, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.52M, bestaande uit 40% salaris en 60% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.98% van de aandelen van het bedrijf, ter waarde $ 1.20M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 4.3 jaar.

Belangrijke informatie

Jay Venkatesan

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris	40.0%
Dienstverband CEO	5.1yrs
Eigendom CEO	4.0%
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Apr 27

Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

Jan 05

We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Sep 11

Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

Oct 05

We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

Aug 18

Analyse CEO-vergoeding

Hoe is Jay Venkatesan's beloning veranderd ten opzichte van Angion Biomedica's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$2m	US$608k	-US$39m
Sep 30 2022	n/a	n/a	-US$17m
Jun 30 2022	n/a	n/a	-US$24m
Mar 31 2022	n/a	n/a	-US$32m
Dec 31 2021	US$3m	US$587k	-US$55m
Sep 30 2021	n/a	n/a	-US$98m
Jun 30 2021	n/a	n/a	-US$100m
Mar 31 2021	n/a	n/a	-US$104m
Dec 31 2020	US$1m	US$570k	-US$80m
Sep 30 2020	n/a	n/a	-US$67m
Dec 31 2019	US$2m	US$473k	-US$41m

Compensatie versus markt: De totale vergoeding ($USD 1.52M ) Jay } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Jay is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jay Venkatesan (51 yo)

5.1yrs

Tenure

US$1,518,849

Compensatie

Dr. Jay R. Venkatesan, Ph D., M.D. MBA., serves as Chairman of Angion Biomedica Corp. since January 2022 and also serves as its President since January 2019 and has been its Chief Executive Officer & Direc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jay Venkatesan	President	5.1yrs	US$1.52m	3.98% $ 1.2m
Jennifer Rhodes	Executive VP	3.4yrs	US$773.65k	0.048% $ 14.6k
Gregory Curhan	Chief Financial Officer	3yrs	US$1.38m	0.013% $ 4.0k
Daniel Iazzetti	Vice President of Human Resources	3.7yrs	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ANGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jay Venkatesan	President	5.1yrs	US$1.52m	3.98% $ 1.2m
Victor Ganzi	Lead Independent Non-Employee Director	5.2yrs	US$93.78k	3.25% $ 978.7k
Gilbert Omenn	Independent Non-Employee Director	3.4yrs	US$76.78k	0.27% $ 80.3k
Karen Wilson	Independent Non-Employee Director	3.2yrs	US$81.28k	0.062% $ 18.7k
Joseph Bonventre	Chairperson of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Allen Nissenson	Independent Non-Employee Director	3.4yrs	US$78.78k	0.031% $ 9.4k
Anupam Agarwal	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Itzhak Goldberg	Chairman Emeritus	25.2yrs	US$854.33k	5.61% $ 1.7m
Matthew Cooper	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Matthew Weir	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Koren	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Sumit Mohan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

74yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ANGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

This company is no longer active

Angion Biomedica Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022

President recently bought US$101k worth of stock

Interim Chief Financial Officer notifies of intention to sell stock

President recently bought US$730k worth of stock

President recently bought US$106k worth of stock

Recent updates

Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. (NasdaqGS:ANGN) from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.47 loss in 1Q 2022)

Insufficient new directors

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Full year 2022 earnings released: US$1.29 loss per share (vs US$1.93 loss in FY 2021)

Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. (NasdaqGS:ANGN) in a reverse merger transaction.

Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

Angion Biomedica Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Price target decreased to US$1.50

We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Second quarter 2022 earnings released: US$0.30 loss per share (vs US$0.57 loss in 2Q 2021)

Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M

Angion Biomedica Corp. Announces Resignation of John F. Neylan as Chief Medical Officer and Head of Research, Effective on August 15, 2022

Price target increased to US$14.75

Angion Biomedica Corp. Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease

Angion to discontinue phase 2 trial of ANG-3070 in patients with kidney disease

President recently bought US$101k worth of stock

First quarter 2022 earnings released: US$0.47 loss per share (vs US$1.57 loss in 1Q 2021)

Angion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary Fibrosis

Price target decreased to US$15.00

Full year 2021 earnings released: US$1.93 loss per share (vs US$5.43 loss in FY 2020)

We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth

Angion Biomedica: Selling At Cash Value

Interim Chief Financial Officer notifies of intention to sell stock

Angion Biomedica Corp. Provides ANG-3070 Program Update

President recently bought US$730k worth of stock

President recently bought US$106k worth of stock

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Key Executive notifies of intention to sell stock

Key Executive notifies of intention to sell stock

Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

Angion Biomedica Corp Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021

Angion Biomedica Corp. Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

Angion Biomedica Corp.(NasdaqGS:ANGN) dropped from Russell Microcap Value Index

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Angion Biomedica Corp. announced that it has received $25 million in funding from Vifor (International) AG

Angion Biomedica Corp. has completed an IPO in the amount of $80 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd